![]() |
市場調查報告書
商品編碼
1519382
2024-2032 年按產品、感染類型、手術類型、最終用戶和地區分類的手術部位感染控制市場報告Surgical Site Infection Control Market Report by Product, Infection Type, Surgery Type, End User, and Region 2024-2032 |
IMARC Group年,全球手術部位感染控制市場規模達46億美元。外科手術的增加、對醫療保健相關感染的認知不斷增強、對病人安全的重視以及醫療保健支出的激增是推動手術部位感染控制市場成長的一些主要因素。
主要市場促進因素:由於人口老化、久坐的生活方式和不健康的飲食習慣,院內感染病例不斷增加,癌症、胃腸道疾病、心血管疾病等慢性病患病率不斷上升。感染控制的採用。此外,各國管理和非管理機構採取的多項有利舉措,例如引入嚴格的指南和專注於感染控制實踐的培訓計劃,正在推動手術部位感染控制市場的發展。
主要市場趨勢:手術部位感染的盛行率不斷上升、感染控制產品的技術不斷進步、微創手術的普及以及嚴格的監管標準的引入預計將推動手術部位感染控制市場的需求。此外,隨著全球醫療保健支出的增加,人們越來越關注改善患者治療結果和減少醫療相關感染(包括 SSI)。這一趨勢預計將推動手術環境中對先進感染控制解決方案的需求。
競爭格局:手術部位感染控制市場的一些領先公司包括 3M 公司、Ansell Limited、Becton Dickinson and Company、bioMerieux SA。 (Institut Merieux)、Covalon Technologies Ltd.、GAMA Healthcare Ltd.、Getinge AB (Carl Bennet AB)、強生公司、Kimberly-Clark Corporation、Molnlycke Health Care AB、Prescient Surgical 和 Steris Corporation 等。
地理趨勢:根據報告,北美目前主導整個市場。該地區是全球手術部位感染控制產品和服務的最大市場之一。市場規模受到手術數量增加、先進的醫療基礎設施、監管環境的廣泛存在、持續的技術創新等因素的影響。的重要性。
挑戰與機會:抗生素抗藥性、合規性問題、成本考量以及不同醫療機構的手術實踐和方案的差異是市場面臨的一些挑戰。然而,醫療技術的進步,例如抗菌塗層、新型手術材料和機器人輔助手術的發展,為手術部位感染控制市場提供了加強手術環境感染控制的新機會。
老年人口增加
全球許多地區正在經歷人口結構變化,其特徵是 65 歲及以上老年人的比例不斷增加。例如,根據世界衛生組織的數據,到 2030 年,世界上每 6 個人中就有 1 人年齡在 60 歲或以上。此時,60歲及以上人口比例將從2020年的10億上升至14億。到 2050 年,全球 60 歲及以上人口將翻倍(21 億)。預計 2020 年至 2050 年間,80 歲及以上的人口數量將增加兩倍,達到 4.26 億。由於免疫系統與年齡相關的變化、組織癒合能力下降以及糖尿病、高血壓和心血管疾病等合併症的存在,老年人更容易受到 SSI 的影響。隨著老年人口的成長,對老年人進行的外科手術數量相應增加,導致對感染控制措施以降低 SSI 風險的需求更高。例如,根據國家醫學圖書館 2021 年 3 月發表的一篇文章,每年對 65 歲及以上的老年人進行近 400 萬例外科手術。與此一致的是,根據美國國家醫學圖書館 2023 年 3 月發表的另一篇文章,在全膝關節置換手術中,76-80 歲老年人的 SSI 率高於 61-65 歲年齡層。這些因素進一步增加了手術部位感染市場的收入。
增加手術程序和醫療基礎設施的發展
世界各地的外科手術數量顯著增加。例如,根據國家醫學圖書館 2020 年 9 月發表的一篇文章,全球 11% 的疾病負擔需要手術介入、麻醉管理或兩者兼而有之。最常見的手術是白內障手術(22.8%)、剖腹產手術(3.8%)、骨折手術(3.27%)和疝氣手術(2.86%)。必要手術佔全部手術的44.2%。此外,醫療保健基礎設施發展舉措,特別是在新興市場,有助於手術部位感染控制市場的成長。印度投資網格(India Investment Grid) 發表的一篇文章稱,到2025 年,公共衛生支出預計將上升至GDP 的2.5%。策略和技術,以盡量減少SSI 的發生率。這包括採用嚴格的方案、先進的滅菌技術、手術器械的抗菌塗層以及在傷口敷料和縫線中使用高科技材料。例如,2023年12月,弗林德斯大學和中國研究人員合作開發了一種具有高度抗感染能力的新型Ag-Ga骨科植入物覆蓋物。這種新型材料可以透過噴塗輕鬆且可控地放置在許多醫療設備上,以保護它們免受感染,同時提供抗發炎作用。此外,2023年10月,Sylke Inc.推出了SYLKE,這是一種由純低過敏性絲素蛋白製成的敷料。 SYLKE 促進手術傷口癒合,減少可能導致疤痕不良的併發症和感染。 SYLKE 尋求透過消除醫用黏合劑相關的導致感染和不良疤痕結果的皮膚損傷來改變手術傷口護理。
研究和臨床試驗的進展
研究和臨床試驗的進展透過促進創新產品的開發、增強治療策略和改善患者預後,在推動手術部位感染控制市場的成長方面發揮著至關重要的作用。例如,2024 年 2 月,致力於改善手術結果的生物製藥公司 PolyPid Ltd. 在招募第 100 名患者後,宣布其 SHIELD II 3 期臨床研究取得了重大進展。這項研究檢視了 D-PLEX100 的功效,該候選產品旨在預防腹部結直腸手術中的手術部位感染 (SSI)。 SHIELD II 試驗的主要結果預計將於 2024 年下半年公佈,約有 40 個地點積極參與研究。此外,研究和臨床試驗有助於確定手術環境中感染預防和控制的最佳實踐和指南。關於術前準備、手術技術、抗菌預防和術後護理的實證建議有助於標準化方案並提高對感染控制措施的依從性,最終降低 SSI 的發生率並改善患者的預後。例如,2023 年 8 月,埃默里大學進行了一項涵蓋 20,000 多名患者的研究,並使用自動化方法提供回饋和評估表現,發現抗生素預防依從性提高了 12%,整體 SSI 下降了 33%。外科感染學會 2023 年年會上公佈的數據表明,獨特的自動化抗生素預防方法可顯著減少手術部位感染。這些因素進一步積極影響手術部位感染控制市場的預測。
IMARC Group提供了全球手術部位感染控制市場報告每個細分市場的主要趨勢分析,以及 2024 年至 2032 年全球、區域和國家層面的預測。我們的報告根據產品、感染類型、手術類型和最終用戶對市場進行了分類。
抗生素預防產品
傷口護理敷料
手術單
手術剪刀
防腐劑和消毒劑
傷口沖洗產品
其他
抗生素預防產品目前在市場上表現出明顯的主導地位
該報告根據產品提供了詳細的市場細分和分析。這包括抗生素預防產品、傷口護理敷料、手術單、手術剪刀、防腐劑和消毒劑、傷口沖洗產品等。報告稱,抗生素預防產品佔全球大部分市場。
根據手術部位感染控制市場前景,抗生素預防在預防手術部位感染(SSI)方面發揮著至關重要的作用,這是醫療機構中一個重要的問題。通常在手術切口前不久施用抗生素,以在潛在細菌污染時達到足夠的組織濃度。給藥時間至關重要,最好在手術切口前 60 分鐘內進行,但某些抗生素和手術可能有例外。此外,預防性抗生素治療方案通常根據不同外科手術的具體要求進行客製化。例如,整形外科手術可能需要金黃色葡萄球菌和鏈球菌的覆蓋,而結直腸手術可能需要針對革蘭氏陰性菌和厭氧菌的額外覆蓋。例如,2024 年 1 月,美國創傷外科協會 (AAST)、歐洲世界外科感染學會 (SIS-E)、全球外科感染聯盟 (GAIS) 和世界急診外科學會 ( WSES)合作制定了針對涉及頭部、大腦、軀幹、顏面部、四肢、皮膚和軟組織的創傷性病變的抗生素預防(AP)的重要指南。
淺表切開SSI
深切SSI
器官或空間SSI
目前,淺切SSI佔據全球大部分市場佔有率
報告還根據感染類型對市場進行了詳細的細分和分析。這包括淺表切口 SSI、深部切口 SSI 和器官或空間 SSI。報告顯示,淺切 SSI 目前佔據最大的市場佔有率。
根據手術部位感染市場概況,淺層切口手術部位感染(SSI)佔所有 SSI 的很大一部分。這些感染發生在術後 30 天內,僅涉及切口的皮膚和皮下組織。它們的特徵通常是手術部位發紅、發熱、腫脹和局部疼痛等症狀。它們是外科手術中最常見的 SSI 類型。它們相對較高的發病率強調了它們在感染控制工作中的重要性。例如,根據國家醫學圖書館 2023 年發表的一篇文章,所有 SSI 患者中 59% 患有淺表 SSI。
剖腹產
胃繞道
白內障手術
牙齒修復
其他
剖腹產目前佔據最大的市場佔有率
該報告根據手術類型對市場進行了詳細的細分和分析。這包括剖腹產、胃繞道手術、白內障手術、牙齒修復等。報告顯示,剖腹產在整個市場中佔有最大佔有率。
剖腹產是全球最常見的外科手術之一。在許多國家,剖腹產率多年來一直在穩步上升。由於手術量如此之大,預防剖腹產中的 SSI 成為感染控制工作的重要重點。此外,剖腹產手術部位由於靠近生殖器和胃腸道,特別容易受到感染,而這些部位含有大量細菌。此外,此手術會破壞皮膚和子宮壁的保護屏障,增加污染的風險。除此之外,剖腹產後的 SSI 可能會對母親和新生兒產生嚴重後果。除了引起母親不適和延長住院時間外,SSI 還會導致子宮內膜炎、傷口裂開、敗血症等併發症,並增加醫療費用。也存在病原體垂直傳播給新生兒的風險,這可能導致新生兒感染。例如,根據世界衛生組織 (WHO) 的資料,剖腹產的使用正在增加,到 2021 年,剖腹產的比例將超過五分之一 (21%)。年,近三分之一(29%) 的新生兒是剖腹產出生的。
醫院
門診手術中心
其他
目前,醫院在市場上佔據明顯主導地位
報告還提供了基於最終用戶的詳細市場細分和分析。這包括醫院、門診手術中心等。根據手術部位感染控制市場報告,醫院在市場上表現出明顯的主導地位。
醫院對手術部位感染(SSI)控制的需求源自於與病人安全、醫療品質、監管要求和財務考量相關的各種因素。預防 SSI 對於確保病人安全和最大限度降低術後併發症的風險至關重要。 SSI 可能導致嚴重的發生率、住院時間延長、醫療費用增加,嚴重時甚至導致死亡。醫院有道德和倫理義務為病人提供安全和高品質的護理,其中包括實施控制 SSI 的措施。此外,醫院越來越注重提供高品質的護理並在社區中保持良好的聲譽。預防 SSI 是醫療保健品質改進工作的一個基本面向。病患、醫療保健專業人員、保險公司和監管機構認為,有效控制 SSI 的醫院更安全、更可靠。
北美洲
美國
加拿大
亞太
中國
日本
印度
韓國
澳洲
印尼
其他
歐洲
德國
法國
英國
義大利
西班牙
俄羅斯
其他
拉丁美洲
巴西
墨西哥
其他
中東和非洲
北美目前主導全球市場
市場研究報告還對所有主要區域市場進行了全面分析,其中包括北美(美國和加拿大);歐洲(德國、法國、英國、義大利、西班牙、俄羅斯等);亞太地區(中國、日本、印度、韓國、澳洲、印尼等);拉丁美洲(巴西、墨西哥等);以及中東和非洲。報告稱,北美目前在全球市場佔據主導地位。
根據手術部位感染控制市場統計數據,北美是全球最大的醫療保健產品和服務市場之一。在此背景下,SSI 控制市場涵蓋廣泛的產品,包括抗菌劑、手術單、手套、滅菌設備、傷口護理產品和監控系統。儘管外科技術和感染控制實踐取得了進步,但 SSI 仍然是北美醫療機構的一個重大問題。 SSI 的盛行率因不同的外科專業和環境而異,但對醫療保健系統造成了巨大的臨床和經濟負擔。例如,2021 年 2 月,Penn Medicine 開設了新的介入支援中心 (ISC),使其成為美國費城西南部最著名的器械處理和手術用品準備設施之一。 ISC 是賓州最早的此類設施之一,工作人員每天對數千件器械進行消毒和包裝,為手術和程序做準備,從基本的剪刀和夾子到複雜的機器人器械。例如,根據美國國家醫學圖書館發表的一篇文章,2024 年 2 月,美國手術部位感染約佔 200 萬例院內感染,這大大提高了術後發病率和死亡率。與此一致,根據麥克馬斯特大學和馬裡蘭大學醫學院於2024 年2 月聯合領導的國際試驗,每年有數千名接受閉合性骨折手術的患者可以透過在酒精中使用碘化物來避免手術部位感染消毒他們的皮膚。
The global surgical site infection control market size reached US$ 4.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.5 Billion by 2032, exhibiting a growth rate (CAGR) of 3.78% during 2024-2032. The increasing surgical procedures, growing awareness about healthcare-associated infections, enhanced focus on patient safety, and surging healthcare expenditure are some of the major factors propelling the surgical site infection control market growth.
Major Market Drivers: The rising cases of hospital-acquired infections and the increasing prevalence of chronic conditions, such as cancer, gastrointestinal disorders, cardiovascular diseases (CVDs), etc., due to the aging population, sedentary lifestyles, and unhealthy eating habits are propelling the adoption of surgical site infection control. Moreover, several favorable initiatives undertaken by the governing and non-governing agencies of various countries, such as the introduction of stringent guidelines and training programs focused on infection control practices, are propelling the surgical site infection control market.
Key Market Trends: The increasing prevalence of surgical site infections, ongoing technological advancements in infection control products, rising adoption of minimally invasive surgeries, and introduction of stringent regulatory standards are expected to propel the surgical site infection control market demand. Moreover, with the rise in healthcare expenditure globally, there is a growing focus on improving patient outcomes and reducing healthcare-associated infections, including SSIs. This trend is expected to drive the demand for advanced infection control solutions in surgical settings.
Competitive Landscape: Some of the leading surgical site infection control market companies are 3M Company, Ansell Limited, Becton Dickinson and Company, bioMerieux SA. (Institut Merieux), Covalon Technologies Ltd., GAMA Healthcare Ltd., Getinge AB (Carl Bennet AB), Johnson & Johnson, Kimberly-Clark Corporation, Molnlycke Health Care AB, Prescient Surgical, and Steris Corporation, among many others.
Geographical Trends: According to the report, North America currently dominates the overall market. The region represents one of the largest markets for surgical site infection control products and services globally. The market size is influenced by factors such as the increase in the number of surgical procedures, advanced healthcare infrastructures, wide presence of regulatory landscape, ongoing technological innovations, etc. The market has been experiencing steady growth due to the increasing awareness about healthcare-associated infections and the importance of infection prevention measures.
Challenges and Opportunities: Antibiotic resistance, compliance issues, cost consideration, and variations in surgical practices and protocols across different healthcare facilities are some of the challenges that the market is facing. However, advances in medical technology, such as the development of antimicrobial coatings, novel surgical materials, and robotic-assisted surgery, offer the surgical site infection control market recent opportunities to enhance infection control in surgical settings.
Rising Geriatric Population
Many regions worldwide are experiencing a demographic shift characterized by a growing proportion of older adults aged 65 and above. For instance, according to the World Health Organization, by 2030, one in every six persons in the world will be 60 or older. At this time, the proportion of the population aged 60 and up will rise from 1 billion in 2020 to 1.4 billion. By 2050, the global population of persons aged 60 and up will double (2.1 billion). The number of people aged 80 and older is anticipated to treble between 2020 and 2050, reaching 426 million. Older adults are more vulnerable to SSIs due to age-related changes in the immune system, reduced tissue healing capacity, and the presence of comorbidities such as diabetes, hypertension, and cardiovascular disease. As the geriatric population grows, there is a corresponding increase in the number of surgical procedures performed on older adults, leading to a higher demand for infection control measures to mitigate the risk of SSIs. For instance, according to an article published by the National Library of Medicine in March 2021, nearly 4 million surgical procedures were performed each year in older adults aged 65 years and above. In line with this, according to another article published by the National Library of Medicine in March 2023, in total knee replacement surgery, the SSI rates were higher in older adults aged 76-80 years when compared with the age group of 61-65 years. These factors are further bolstering the surgical site infection market revenue.
Increasing Surgical Procedure and Healthcare Infrastructure Development
There has been a significant increase in surgical procedures across the world. For instance, according to an article published by the National Library of Medicine, in September 2020, 11% of the world's illness burden necessitates surgical intervention, anesthetic management, or both. The most common procedures were for cataracts (22.8%), Caesareans (3.8%), fracture surgeries (3.27%), and hernias (2.86%). The necessary operations made up 44.2% of all surgeries. Moreover, healthcare infrastructure development initiatives, particularly in emerging markets, contribute to the growth of the surgical site infection control market. According to an article published by the India Investment Grid, public health expenditure is expected to rise to 2.5% of GDP by 2025. Apart from this, healthcare facilities and providers are increasingly investing in preventive strategies and technologies to minimize the incidence of SSIs. This includes the adoption of stringent protocols, advanced sterilization techniques, antimicrobial coatings for surgical instruments, and the utilization of high-tech materials in wound dressings and sutures. For instance, in December 2023, Flinders University and Chinese researchers collaborated to develop a new Ag-Ga orthopedic implant covering that is highly resistant to infection. The novel material could be readily and controllably put by spray-casting on numerous medical devices to protect them from infection while simultaneously providing an anti-inflammatory impact. Moreover, in October 2023, Sylke Inc. introduced SYLKE, the dressing manufactured from pure hypoallergenic silk fibroin. SYLKE promotes healing in surgical wounds and reduces complications and infections that might cause poor scarring. SYLKE seeks to transform surgical wound care by removing medical adhesive-related skin damage that causes infections and poor scarring outcomes.
Advances in Research Studies and Clinical Trials
Advances in research studies and clinical trials play a crucial role in driving growth in the surgical site infection control market by facilitating the development of innovative products, enhancing treatment strategies, and improving patient outcomes. For instance, in February 2024, PolyPid Ltd., a biopharmaceutical company dedicated to improving surgical outcomes, announced considerable progress in its SHIELD II Phase 3 clinical study, after enrolling its 100th patient. This research looked at the efficacy of D-PLEX100, a product candidate intended to prevent surgical site infections (SSIs) in abdominal colorectal procedures. Top-line results from the SHIELD II trial were expected in the second half of 2024, with about 40 locations actively participating in the study. Moreover, research studies and clinical trials contribute to the identification of best practices and guidelines for infection prevention and control in surgical settings. Evidence-based recommendations regarding preoperative preparation, surgical techniques, antimicrobial prophylaxis, and postoperative care help standardize protocols and improve adherence to infection control measures, ultimately reducing the incidence of SSIs and improving patient outcomes. For instance, in August 2023, Emory University performed research which included over 20,000 patients and used automated methods to provide feedback and evaluate performance, found a 12% increase in antibiotic prophylactic compliance and a 33% decrease in overall SSIs. Data presented at the Surgical Infection Society's 2023 annual meeting showed that a unique automated antibiotic prophylaxis approach significantly reduces surgical site infections. These factors are further positively influencing the surgical site infection control market forecast.
IMARC Group provides an analysis of the key trends in each sub-segment of the global surgical site infection control market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product, infection type, surgery type, and end user.
Antibiotic Prophylaxis Products
Wound Care Dressings
Surgical Drapes
Surgical Clippers
Antiseptics and Disinfectants
Wound Irrigation Products
Others
Antibiotic prophylaxis products currently exhibit a clear dominance in the market
The report has provided a detailed breakup and analysis of the market based on the product. This includes antibiotic prophylaxis products, wound care dressings, surgical drapes, surgical clippers, antiseptics and disinfectants, wound irrigation products, and others. According to the report, antibiotic prophylaxis products account for the majority of the global market share.
According to the surgical site infection control market outlook, antibiotic prophylaxis plays a crucial role in preventing surgical site infections (SSIs), which are a significant concern in healthcare settings. Antibiotics are usually administered shortly before surgical incision to achieve adequate tissue concentrations at the time of potential bacterial contamination. The timing of administration is critical and should ideally occur within 60 minutes before the surgical incision, although exceptions may exist for certain antibiotics and procedures. Moreover, prophylactic antibiotic regimens are often tailored to the specific requirements of different surgical procedures. For example, orthopedic surgeries may require coverage against Staphylococcus aureus and streptococci, while colorectal surgeries may necessitate additional coverage against gram-negative and anaerobic bacteria. For instance, in January 2024, the American Association for the Surgery of Trauma (AAST), the World Surgical Infection Society Europe (SIS-E), the Global Alliance for Infection in Surgery (GAIS), and the World Society of Emergency Surgery (WSES) collaborated to develop important guidelines for antibiotic prophylaxis (AP) in cases of traumatic lesions involving the head, brain, torso, maxillofacial region, extremities, skin, and soft tissues.
Superficial Incisional SSI
Deep Incisional SSI
Organ or Space SSI
Currently, superficial incisional SSI accounts for the majority of the global market share
A detailed breakup and analysis of the market based on the infection type have also been provided in the report. This includes superficial incisional SSI, deep incisional SSI, and organ or space SSI. According to the report, superficial incisional SSI currently holds the largest market share.
According to the surgical site infection market overview, superficial incisional surgical site infections (SSIs) represent a significant portion of all SSIs. These infections occur within 30 days after the operation and involve only the skin and subcutaneous tissue of the incision. They are often characterized by symptoms such as redness, warmth, swelling, and localized pain at the surgical site. They are among the most common types of SSIs encountered in surgical practice. Their relatively high incidence underscores their importance in infection control efforts. For instance, according to an article published by the National Library of Medicine in 2023, 59% of the total SSI patients had superficial SSI.
Cesarean Section
Gastric Bypass
Cataract Surgery
Dental Restoration
Others
Cesarean section currently holds the largest market share
The report has provided a detailed breakup and analysis of the market based on the surgery type. This includes cesarean section, gastric bypass, cataract surgery, dental restoration, and others. According to the report, the cesarean section holds the largest share in the overall market.
Cesarean sections are one of the most common surgical procedures globally. In many countries, the rates of C-section deliveries have been increasing steadily over the years. With such a high volume of procedures, the prevention of SSIs in C-sections becomes a significant focus of infection control efforts. Moreover, the surgical site in a Cesarean section is particularly vulnerable to infection due to its proximity to the genital and gastrointestinal tracts, which harbor numerous bacteria. Additionally, the procedure involves breaching the protective barriers of the skin and uterine wall, increasing the risk of contamination. Apart from this, SSIs following Cesarean sections can have serious consequences for both the mother and the newborn. In addition to causing discomfort and prolonging hospital stays for the mother, SSIs can lead to complications such as endometritis, wound dehiscence, sepsis, and increased healthcare costs. There's also a risk of vertical transmission of pathogens to the newborn, which can result in neonatal infections. For instance, according to World Health Organization (WHO) data, the use of cesarean sections is increasing, accounting for more than one in every five (21%) childbirths in 2021. This figure is expected to rise further over the next decade, with almost one-third (29%) of all births by cesarean section by 2030.
Hospitals
Ambulatory Surgical Centers
Others
Currently, hospitals exhibit a clear dominance in the market
A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals, ambulatory surgical centers, and others. According to the surgical site infection control market report, hospitals exhibit a clear dominance in the market.
The demand for surgical site infection (SSI) control in hospitals arises from various factors related to patient safety, healthcare quality, regulatory requirements, and financial considerations. Preventing SSIs is essential for ensuring patient safety and minimizing the risk of postoperative complications. SSIs can lead to significant morbidity, prolonged hospital stays, increased healthcare costs, and in severe cases, mortality. Hospitals have a moral and ethical obligation to provide safe and high-quality care to their patients, which includes implementing measures to control SSIs. Moreover, hospitals are increasingly focused on delivering high-quality care and maintaining a positive reputation within their communities. Preventing SSIs is a fundamental aspect of healthcare quality improvement efforts. Hospitals that effectively control SSIs are perceived as safer and more reliable by patients, healthcare professionals, insurers, and regulatory agencies.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America currently dominates the global market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America currently dominates the global market.
According to the surgical site infection control market statistics, North America represents one of the largest markets for healthcare products and services globally. Within this context, the SSI control market encompasses a wide range of products, including antimicrobial agents, surgical drapes, gloves, sterilization equipment, wound care products, and surveillance systems. Despite advances in surgical techniques and infection control practices, SSIs remain a significant concern in North American healthcare facilities. The prevalence of SSIs varies across different surgical specialties and settings but represents a substantial clinical and economic burden on healthcare systems. For instance, in February 2021, Penn Medicine opened its new Interventional Support Center (ISC), making it one of the most prominent instrument processing and surgical supply preparation facilities in Southwest Philadelphia, United States. The ISC is one of Pennsylvania's first facilities of its sort, with staff sterilizing and packaging thousands of instruments daily in preparation for surgeries and procedures, ranging from basic scissors and clamps to complex robotic instruments. For instance, according to an article published by the National Library of Medicine, in February 2024, surgical site infections accounted for approximately two million nosocomial infections in the U.S., which considerably raises postoperative morbidity and mortality rates. In line with this, according to the international trial co-led by McMaster University and the University of Maryland School of Medicine in February 2024, thousands of patients yearly undergoing surgery for a closed fracture may avoid surgical site infections by using iodine povacrylex in alcohol to disinfect their skin.
3M Company
Ansell Limited
Becton Dickinson and Company
bioMerieux SA. (Institut Merieux)
Covalon Technologies Ltd.
GAMA Healthcare Ltd.
Getinge AB (Carl Bennet AB)
Johnson & Johnson
Kimberly-Clark Corporation
Molnlycke Health Care AB
Prescient Surgical
Steris Corporation
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
May 2024: Nanordica Medical, an Estonian medical technology firm, received €1.75 million to enter the market with first-in-class wound care solutions that treat serious wounds.
April 2024: Vomaris launched PowerHeal, a bioelectric bandage approved by the FDA for over-the-counter (OTC) use in the management of wounds.
February 2024: PolyPid Ltd., a biopharmaceutical company dedicated to improving surgical outcomes, announced considerable progress in its SHIELD II Phase 3 clinical study, after enrolling its 100th patient. This research looked at the efficacy of D-PLEX100, a product candidate intended to prevent surgical site infections (SSIs) in abdominal colorectal procedures.